CAMBRIDGE, MASS. & RIYADH, SAUDI ARABIA -- In a landmark initiative poised to transform healthcare in the Kingdom of Saudi Arabia, Boston Oncology and King Fahd Medical City (KFMC) have signed a Letter of Intent to collaborate on the localization of Cell & Gene Therapy.

The signing ceremony, attended by His Excellency Eng. Abdulaziz AlRamaih, Deputy Minister of Health for Planning and Development, marks a significant step forward in advancing the Kingdom’s medical capabilities and achieving the ambitious goals set forth in Vision 2030.

A Milestone in Healthcare Transformation

Dr. Fahad Al-Ghofaili, KFMC CEO, expressed his enthusiasm: “Localizing Cell & Gene Therapy in KFMC is an important step to increase local capabilities in advanced treatments and medical technologies, contributing to the goals of the Healthcare Transformation Project.” [Translated from Arabic]

Impact for Patients

Boston Oncology, renowned for its customer-centered model, brings extensive expertise in localizing technology. Laser-focused on the real-world needs of patients and hospitals, Boston Oncology is positioned to provide cutting-edge technologies and Cell & Gene Therapies through this partnership. This collaboration will establish a local treatment option, relieving bottlenecks in therapy provision and improving patient outcomes. The resulting Research & Development and clinical trials will significantly contribute to innovative advancements in the healthcare sector of Saudi Arabia.

Dr. Abdullah Baaj, CEO of Boston Oncology, described the partnership: “KFMC brings world-class clinicians and infrastructure, making it a destination for patients throughout the region. Joining forces to localize Cell & Gene Therapy is a transformative step towards our mission to impact the lives of one billion patients.”

About Boston Oncology Cell & Gene Therapy

Boston Oncology is an innovative life science company with a mission to impact the lives of one billion patients by 2030. With corporate headquarters in Cambridge, Massachusetts, and operations throughout the world, the company is focused on bringing patient-centered solutions and advanced treatment modalities to growing markets. Its new Cell & Gene Therapy entity establishes a fully localized offering to deliver personalized treatments that address the unique genetic profiles of patients. By partnering with leading medical institutions and leveraging leading-edge technologies, Boston Oncology CGT is expanding the company’s legacy of transformative advancements in healthcare.